UE vs. GSK
Compare and contrast key facts about Urban Edge Properties (UE) and GlaxoSmithKline plc (GSK).
Performance
UE vs. GSK - Performance Comparison
Loading graphics...
UE vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
UE Urban Edge Properties | 5.19% | -7.17% | 21.70% | 35.31% | -22.82% | 51.71% | -28.98% | 20.91% | -32.00% | -4.02% |
GSK GlaxoSmithKline plc | 13.45% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
Fundamentals
UE:
$2.61B
GSK:
$112.75B
UE:
$0.75
GSK:
$2.78
UE:
26.70
GSK:
19.82
UE:
0.32
GSK:
1.33
UE:
5.39
GSK:
3.54
UE:
2.03
GSK:
6.90
UE:
$471.94M
GSK:
$31.95B
UE:
$323.07M
GSK:
$23.18B
UE:
$317.99M
GSK:
$11.62B
Returns By Period
In the year-to-date period, UE achieves a 5.19% return, which is significantly lower than GSK's 13.45% return. Over the past 10 years, UE has underperformed GSK with an annualized return of 1.40%, while GSK has yielded a comparatively higher 5.74% annualized return.
UE
- 1D
- -0.35%
- 1M
- -5.01%
- YTD
- 5.19%
- 6M
- -0.43%
- 1Y
- 9.35%
- 3Y*
- 14.15%
- 5Y*
- 7.25%
- 10Y*
- 1.40%
GSK
- 1D
- 1.77%
- 1M
- -6.66%
- YTD
- 13.45%
- 6M
- 30.03%
- 1Y
- 48.15%
- 3Y*
- 20.43%
- 5Y*
- 8.75%
- 10Y*
- 5.74%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
UE vs. GSK — Risk / Return Rank
UE
GSK
UE vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Urban Edge Properties (UE) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| UE | GSK | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.40 | 1.70 | -1.31 |
Sortino ratioReturn per unit of downside risk | 0.72 | 2.30 | -1.57 |
Omega ratioGain probability vs. loss probability | 1.09 | 1.29 | -0.20 |
Calmar ratioReturn relative to maximum drawdown | 0.62 | 3.25 | -2.63 |
Martin ratioReturn relative to average drawdown | 1.69 | 7.56 | -5.87 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| UE | GSK | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.40 | 1.70 | -1.31 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.27 | 0.36 | -0.08 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.04 | 0.25 | -0.21 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.07 | 0.33 | -0.26 |
Correlation
The correlation between UE and GSK is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
UE vs. GSK - Dividend Comparison
UE's dividend yield for the trailing twelve months is around 3.90%, more than GSK's 3.19% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
UE Urban Edge Properties | 3.90% | 3.96% | 3.16% | 3.50% | 4.54% | 3.16% | 5.26% | 4.59% | 5.29% | 3.45% | 2.98% | 3.41% |
GSK GlaxoSmithKline plc | 3.19% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
Drawdowns
UE vs. GSK - Drawdown Comparison
The maximum UE drawdown since its inception was -71.78%, which is greater than GSK's maximum drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for UE and GSK.
Loading graphics...
Drawdown Indicators
| UE | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -71.78% | -55.70% | -16.08% |
Max Drawdown (1Y)Largest decline over 1 year | -16.07% | -14.80% | -1.27% |
Max Drawdown (5Y)Largest decline over 5 years | -32.08% | -50.10% | +18.02% |
Max Drawdown (10Y)Largest decline over 10 years | -71.78% | -50.10% | -21.68% |
Current DrawdownCurrent decline from peak | -10.36% | -9.07% | -1.29% |
Average DrawdownAverage peak-to-trough decline | -22.41% | -18.90% | -3.51% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.86% | 6.37% | -0.51% |
Volatility
UE vs. GSK - Volatility Comparison
The current volatility for Urban Edge Properties (UE) is 3.86%, while GlaxoSmithKline plc (GSK) has a volatility of 7.26%. This indicates that UE experiences smaller price fluctuations and is considered to be less risky than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| UE | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 3.86% | 7.26% | -3.40% |
Volatility (6M)Calculated over the trailing 6-month period | 12.96% | 19.71% | -6.75% |
Volatility (1Y)Calculated over the trailing 1-year period | 23.78% | 28.43% | -4.65% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 26.56% | 24.74% | +1.82% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.53% | 22.72% | +11.81% |
Financials
UE vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Urban Edge Properties and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
UE vs. GSK - Profitability Comparison
UE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Urban Edge Properties reported a gross profit of 78.76M and revenue of 119.56M. Therefore, the gross margin over that period was 65.9%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, GlaxoSmithKline plc reported a gross profit of 5.49B and revenue of 7.90B. Therefore, the gross margin over that period was 69.5%.
UE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Urban Edge Properties reported an operating income of 33.29M and revenue of 119.56M, resulting in an operating margin of 27.8%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, GlaxoSmithKline plc reported an operating income of 179.89M and revenue of 7.90B, resulting in an operating margin of 2.3%.
UE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Urban Edge Properties reported a net income of 12.42M and revenue of 119.56M, resulting in a net margin of 10.4%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, GlaxoSmithKline plc reported a net income of 627.73M and revenue of 7.90B, resulting in a net margin of 7.9%.